BR112012007778A2 - método para identificar lúpus, método para avaliar se um sujeito está em risco de desenvolver lúpus, medicamentos para tratar uma condição de lupus, método e usos de um agente terapêutico. - Google Patents

método para identificar lúpus, método para avaliar se um sujeito está em risco de desenvolver lúpus, medicamentos para tratar uma condição de lupus, método e usos de um agente terapêutico. Download PDF

Info

Publication number
BR112012007778A2
BR112012007778A2 BR112012007778-3A BR112012007778A BR112012007778A2 BR 112012007778 A2 BR112012007778 A2 BR 112012007778A2 BR 112012007778 A BR112012007778 A BR 112012007778A BR 112012007778 A2 BR112012007778 A2 BR 112012007778A2
Authority
BR
Brazil
Prior art keywords
lupus
sle
risk
variation
snp
Prior art date
Application number
BR112012007778-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Timothy W. Behrens
Robert R. Graham
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BR112012007778A2 publication Critical patent/BR112012007778A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012007778-3A 2009-10-07 2010-10-06 método para identificar lúpus, método para avaliar se um sujeito está em risco de desenvolver lúpus, medicamentos para tratar uma condição de lupus, método e usos de um agente terapêutico. BR112012007778A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27851009P 2009-10-07 2009-10-07
US61/278,510 2009-10-07
PCT/US2010/051589 WO2011044205A1 (en) 2009-10-07 2010-10-06 Methods for treating, diagnosing, and monitoring lupus

Publications (1)

Publication Number Publication Date
BR112012007778A2 true BR112012007778A2 (pt) 2020-08-11

Family

ID=43857111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007778-3A BR112012007778A2 (pt) 2009-10-07 2010-10-06 método para identificar lúpus, método para avaliar se um sujeito está em risco de desenvolver lúpus, medicamentos para tratar uma condição de lupus, método e usos de um agente terapêutico.

Country Status (9)

Country Link
US (3) US20130034544A1 (https=)
EP (3) EP2486152B1 (https=)
JP (2) JP5937008B2 (https=)
KR (2) KR101824744B1 (https=)
CN (2) CN113025703A (https=)
BR (1) BR112012007778A2 (https=)
CA (1) CA2777055C (https=)
RU (2) RU2596391C2 (https=)
WO (1) WO2011044205A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113025703A (zh) * 2009-10-07 2021-06-25 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控狼疮的方法
US20130310266A1 (en) * 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
KR20140034529A (ko) 2012-09-12 2014-03-20 삼성전기주식회사 전기 동도금 장치
KR101491214B1 (ko) * 2012-10-10 2015-02-06 가톨릭대학교 산학협력단 １ｑ２５．１(RABGAP1L) 위치, 6p21.32 (C4) 위치 및 １０ｑ２１．３위치의 ＤＮＡ 복제 수 변이 검출용 프라이머를 포함하는 전신성 홍반성 루푸스 발병 위험도 예측용 조성물
WO2014058254A1 (ko) * 2012-10-10 2014-04-17 가톨릭대학교 산학협력단 １ｑ２５．１(RABGAP1L) 위치, 6P21.32 (C4) 위치 및 １０ｑ２１．３위치의 ＤＮＡ 복제 수 변이 검출용 프라이머를 포함하는 전신성 홍반성 루푸스 발병 위험도 예측용 조성물
SG11201606843SA (en) * 2014-03-21 2016-10-28 Agency Science Tech & Res Fusion genes in cancer
DE102017107661A1 (de) 2017-04-10 2018-10-11 Universität Rostock SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort
KR20190034511A (ko) 2019-03-22 2019-04-02 아주대학교산학협력단 Aimp1을 포함하는 전신 홍반성 루프스 진단용 바이오마커 조성물 및 이를 이용한 전신 홍반성 루프스 진단 방법
WO2021127589A1 (en) * 2019-12-18 2021-06-24 The Children's Hospital Of Philadelphia Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same
AU2022312774B9 (en) * 2021-07-15 2026-04-09 Fujifilm Corporation Cell quality management method and cell production method

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
AU6534600A (en) * 1999-08-09 2001-03-05 Uab Research Foundation Genetic polymorphism in the il-10 promoter
AU2001265121A1 (en) 2000-05-30 2001-12-11 Applera Corporation Methods for detecting target nucleic acids using coupled ligation and amplification
AU2001286949A1 (en) * 2000-08-29 2002-03-13 Genaissance Pharmaceuticals, Inc. Haplotypes of the bf gene
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
EP1334113A4 (en) 2000-10-20 2007-08-08 Expression Diagnostics Inc EVALUATION OF LEUCOCYTAIRE EXPRESSION LEVEL
US7205106B1 (en) 2001-07-20 2007-04-17 Roche Molecular Systems, Inc. Association of polymorphisms in IL4-related genes with autoimmune disease
JP2003061677A (ja) 2001-08-28 2003-03-04 Olympus Optical Co Ltd 全身性エリテマトーデスの感受性遺伝子およびその使用
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
US7022476B2 (en) 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
US7584058B2 (en) * 2003-02-27 2009-09-01 Methexis Genomics N.V. Genetic diagnosis using multiple sequence variant analysis
CA2519476A1 (en) 2003-03-18 2004-09-30 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2005086872A2 (en) 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
DE102005003686A1 (de) 2005-01-26 2006-08-03 Rohde & Schwarz Gmbh & Co. Kg Anordnung zum Glätten des einem Verbraucher zugeführten Verbraucherstromes
RU2421242C2 (ru) * 2005-07-25 2011-06-20 Трабьон Фармасьютикалз, Инк. Применение однократной дозы cd20-специфических связывающих молекул
DK2327792T3 (da) 2005-08-05 2014-01-13 Genentech Inc Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
US20070238094A1 (en) * 2005-12-09 2007-10-11 Baylor Research Institute Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis
CN101374964B (zh) * 2005-12-09 2013-07-17 贝勒研究院 外周血液白细胞转录模式的模块水平分析
CN101443040A (zh) * 2006-03-16 2009-05-27 基因技术股份有限公司 用cd4抗体治疗狼疮的方法
CA2645322A1 (en) 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
US20070269827A1 (en) 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
EP2639317B1 (en) * 2006-09-11 2015-03-04 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
WO2008087647A2 (en) * 2007-01-19 2008-07-24 Yeda Research And Development Co. Ltd. Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (sle)
US7695916B2 (en) * 2007-03-22 2010-04-13 Celera Corporation Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof
WO2008144761A2 (en) * 2007-05-21 2008-11-27 Genentech, Inc. Methods and compositions for identifying and treating lupus
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
WO2009065132A1 (en) * 2007-11-16 2009-05-22 Oklahoma Medical Research Foundation Predicting and diagnosing patients with autoimmune disease
US20090307180A1 (en) * 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
DE102008031958A1 (de) 2008-07-07 2010-01-14 Klebchemie M.G. Becker Gmbh & Co. Kg Verfahren zum Laminieren von Hochglanzoberflächen
CN102224258A (zh) * 2008-09-26 2011-10-19 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监测狼疮的方法
CN113025703A (zh) 2009-10-07 2021-06-25 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控狼疮的方法

Also Published As

Publication number Publication date
US20160273044A1 (en) 2016-09-22
CN106929568A (zh) 2017-07-07
RU2012118596A (ru) 2013-11-20
EP3219813A3 (en) 2018-01-10
CA2777055A1 (en) 2011-04-14
EP3839068A3 (en) 2021-10-20
JP2013507127A (ja) 2013-03-04
US20130034544A1 (en) 2013-02-07
EP2486152B1 (en) 2017-12-06
EP3219813A2 (en) 2017-09-20
KR20120100969A (ko) 2012-09-12
CN102803509A (zh) 2012-11-28
CA2777055C (en) 2021-04-06
EP3219813B1 (en) 2020-11-18
HK1176384A1 (zh) 2013-07-26
JP6321717B2 (ja) 2018-05-09
EP3839068A2 (en) 2021-06-23
RU2596391C2 (ru) 2016-09-10
EP2486152A1 (en) 2012-08-15
US10053734B2 (en) 2018-08-21
JP5937008B2 (ja) 2016-06-22
CN113025703A (zh) 2021-06-25
JP2017012158A (ja) 2017-01-19
US20190211398A1 (en) 2019-07-11
KR20180012344A (ko) 2018-02-05
RU2016131167A (ru) 2018-12-07
KR101953075B1 (ko) 2019-02-27
EP2486152A4 (en) 2013-05-22
WO2011044205A1 (en) 2011-04-14
KR101824744B1 (ko) 2018-03-15

Similar Documents

Publication Publication Date Title
BR112012007778A2 (pt) método para identificar lúpus, método para avaliar se um sujeito está em risco de desenvolver lúpus, medicamentos para tratar uma condição de lupus, método e usos de um agente terapêutico.
KR101947093B1 (ko) 루푸스를 확인 및 치료하기 위한 방법 및 조성물
CN102803509B (zh) 用于治疗、诊断和监控狼疮的方法
HK1237003A1 (en) Methods for treating, diagnosing, and monitoring lupus
HK1176384B (en) Methods for treating, diagnosing, and monitoring lupus
HK1209459B (zh) 用於鑒定和治療狼瘡的方法和組合物
HK1189246B (en) Methods and compositions for identifying and treating lupus

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]